References
- Chompret A, Brugieres L, Ronsin M, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer. 2000;82:1932-7. https://doi.org/10.1054/bjoc.2000.1167
- Li FP, Fraumeni JF Jr. Prospective study of a family cancer syndrome. JAMA. 1982;247:2692-4. https://doi.org/10.1001/jama.1982.03320440040031
- Hisada M, Garber JE, Fung CY, Fraumeni JF Jr, Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst. 1998;90:606-11. https://doi.org/10.1093/jnci/90.8.606
- Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988;48:5358-62.
- American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003;21:2397-406. https://doi.org/10.1200/JCO.2003.03.189
- Speicher MR, Carter NP. The new cytogenetics: blurring the boundaries with molecular biology. Nat Rev Genet. 2005;6:782-92. https://doi.org/10.1038/nrg1692
- Birch JM, Hartley AL, Tricker KJ, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li- Fraumeni families. Cancer Res. 1994;54:1298-304.
- Eeles RA. Germline mutations in the TP53 gene. Cancer Surv. 1995;25:101-24.
- Leroy K, Haioun C, Lepage E, et al; Groupe d'Etude des Lymphomes de l'Adulte. p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol. 2002;13:1108-15. https://doi.org/10.1093/annonc/mdf185
- Berns EM, Foekens JA, Vossen R, et al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res. 2000;60:2155-62.
Cited by
- Germline TP53 Mutation and Clinical Characteristics of Korean Patients With Li-Fraumeni Syndrome vol.36, pp.5, 2014, https://doi.org/10.3343/alm.2016.36.5.463